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Proximity-dependent biotin identification (BioID)
reveals a dynamic LSD1–CoREST interactome
during embryonic stem cell differentiation†
Claire E. Barnes,a David M. English,a Megan Broderick,a Mark O. Collins bc and
Shaun M. Cowley *a
Lysine specific demethylase 1 (LSD1) regulates gene expression as part of the CoREST complex, along
with co-repressor of REST (CoREST) and histone deacetylase 1 (HDAC1). CoREST is recruited to specific
genomic loci by core components and numerous transient interactions with chromatin-associated
factors and transcription factors. We hypothesise that many of these weaker and transient associations
may be difficult to identify using traditional co-immunoprecipitation methods. We have therefore
employed proximity-dependent biotin-identification (BioID) with four different members of the CoREST
complex, in three different cell types, to identify a comprehensive network of LSD1/CoREST associated
proteins. In HEK293T cells, we identified 302 CoREST-associated proteins. Among this group were 16 of
18 known CoREST components and numerous novel associations, including readers (CHD3, 4, 6, 7 and 8),
writers (KMT2B and KMT2D) and erasers (KDM2B) of histone methylation. However, components of other
HDAC1 containing complexes (e.g. Sin3) were largely absent. To examine the dynamic nature of the
CoREST interactome in a primary cell type, we replaced endogenous LSD1 with BirA*-LSD1 in embryonic
stem (ES) cells and performed BioID in pluripotent, early- and late-differentiating environments. We
identified 156 LSD1-associated proteins of which 67 were constitutively associated across all three time-
points (43%), including novel associations with the MMB and ChAHP complexes, implying that the majority
of interactors are both dynamic and cell type dependent. In total, we have performed 16 independent
BioID experiments for LSD1 in three different cell types, producing a definitive network of LSD1-assoicated
proteins that should provide a major resource for the field.
Introduction
The ability to regulate chromatin structure is a critical step in
determining patterns of gene expression in eukaryotic cells.
The core histones (H2A, H2B, H3 and H4) are subject to a
myriad of post-translational modifications (PTM) that alter
their chemical properties and act as binding sites for the
recruitment of additional proteins. Lysine acetylation (Lys-Ac)
is a common PTM in histones, occurring primarily on the Lys
rich N-terminal tails of histones.1 Addition of the acetyl-moiety
neutralizes the positive charge on the Lys, reducing the asso-
ciation of the histone tail with the DNA backbone and negative
patches on neighbouring nucleosomes. Lys-Ac is a dynamic
modification whose levels are determined by the competing
activities of histone acetyl transferases (HATs) and histone
deacetylases (HDACs). Among the 18 HDACs found in
mammalian cells the highly related enzymes, HDAC1 and HDAC2
(HDAC1/2), contribute approximately half of the total deacetylase
activity,2,3 as part of four canonical multi-protein complexes: Sin3,
NuRD, CoREST and MiDAC.4,5 Each complex typically contains
3–6 core proteins with a coterie of additional subunits thought to
add functionality by directing genomic location and substrate
specificity. There is relatively little overlap in terms of protein
components between the complexes and knockout studies
suggest that each of the four has a unique function during
development.4 Given the multitude of protein–protein inter-
actions present within each of these complexes, a number of
molecular details still remain to be addressed. In particular, the
identity and number of complex components present at any
given time need to be elucidated. Indeed, there is evidence to
suggest that HDAC1/2 complexes are able to adapt their auxiliary
components to suit different cell types.6
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The core CoREST complex is comprised of three components:
lysine specific demethylase 1 (LSD1/KDM1A), co-repressor of RE1-
silencing transcription factor (CoREST) and HDAC1. LSD1 was the
first protein demethylase to be identified and acts to remove the
mono- and di-methyl moieties from Lys4 on histone H3 (H3K4me/
me2),7–10 a positive mark in regards to transcriptional activity,
although it potentially has additional histone substrates.11,12 The
amine oxidase domain of LSD1 contains a long helical ‘Tower’
domain which forms a heterodimer with CoREST.13–16 CoREST
binding stimulates LSD1 demethylase activity,9,17 it also contains
an N-terminal ELM2/SANT domain that binds to HDAC118,19 and
a second SANT domain in the C-terminus. The combination of
demethylase/deacetylase activities within the core LSD1/CoREST/
HDAC1 complex allows for the coordinated demethylation of
H3K4me/me2 and deacetylation of the histone H3 tail, promoting
transcriptional repression.9,16,17,20,21 Indeed, in vitro studies
with purified LSD1/CoREST and cellular experiments suggest
that the deacetylated H3 tail may be the preferred LSD1 substrate
for demethylation.17,20 In addition to the core components, the
CoREST complex contains a number of additional chromatin
associated subunits, such as PHF21A, HMG20A/B and CTBP1/2
which enable recruitment to specific genomic loci.7,9
The association of LSD1/CoREST with both core components
and accessory proteins is critical to their function in cells. While
the majority of LSD1-interacting proteins have been identified
by co-immunoprecipitation methods, we hypothesise that this
will likely miss many transiently associated proteins, including
substrates of LSD1 and HDAC1. We have therefore utilised a
proximity-dependent biotin identification (BioID) approach.
BioID utilizes a biotin ligase fused to the protein of interest
such that proximal proteins (B10 nm) are labelled with biotin,
which can then be identified by streptavidin pull-down followed
by quantitative mass-spectrometry.22,23 The advantage of the
BioID approach is that unlike co-purification methods, it does
not require direct binding and thus enables identification of
transiently associated proteins, or those in close proximity.
To increase the confidence of our experiments we tagged four
separate components of the CoREST complex (LSD1, CoREST1,
HDAC1 and PHF21A) with the biotin ligase, BirA* and identified
an extensive protein network in HEK293T and embryonic stem
(ES) cells. Retaining only targets identified with 3 out of 4 bait
proteins, we identified 302 CoREST-associated proteins in
HEK293T cells. Among this group were 16 of 18 known CoREST
components and numerous novel associations, including
readers (CHD3, 4, 6, 7 and 8), writers (KMT2B and KMT2D) and
erasers (KDM2B) of histone methylation. However, components of
other HDAC1 containing complexes (e.g. Sin3A, NuRD) were
largely absent, suggesting that CoREST functions in a chromatin
based environment that is independent of these related
complexes. To examine the role of CoREST in different cell types,
we replaced endogenous LSD1 with BirA*-LSD1 in embryonic
stem (ES) cells and performed BioID in pluripotent, early-
and late-differentiating environments. In total, we identified 156
LSD1-associated proteins of which 67 were constitutively
associated across all three time-points (43%), including novel
associations with the MMB and ChAHP complexes. These data
imply that the majority of CoREST interactions (56%) are dynamic
and highly dependent on cell type. Furthermore, similar to
HEK293T cell data, the LSD1 interactome in embryonic stem
(ES) cells was lacking components of other HDAC1-containing
complexes. Our data suggests that CoREST occupies a discrete
space in the nucleus with a specific subset of transcription factors
and chromatin modifiers that appears to be largely distinct from
other HDAC1-containing complexes. Our application of BioID has
identified a definitive dataset of LSD1 associated proteins and
novel interactomes for CoREST1 and PHF21A, that should be of
wide utility to the field.
Results
Efficient labelling and identification of LSD1/CoREST/HDAC1
proximal proteins using BioID
The core ternary CoREST complex (Fig. 1A) is recruited to
specific genomic loci by co-factors with histone recognition
motifs (e.g. PHF21A, PHD domain9) and transcription factors,
such as REST.24 In addition, LSD1 and HDAC1 are both
enzymes, whose range of histone and non-histone substrates
are likely to be transiently associated. Therefore, an under-
standing of the local protein environment around the CoREST
complex will be instrumental in defining its role in cells at a
molecular level. To this end, we employed BioID methodology,
which utilizes a promiscuous version of the E. coli biotin ligase
enzyme, BirA (BirA*-R118G22,23), fused to the protein of inter-
est, allowing labelling and identification of proximal proteins
(within approx. 10 nm). The advantage of this approach is that it
allows the identification of both binding partners and transiently
associated proteins such as substrates. To investigate the proximal
protein environment of the CoREST complex five BirA* fusion
protein constructs were generated (Fig. 1B). These included the
three core protein components, LSD1, CoREST1 and HDAC1
(Fig. 1A); and PHF21A which forms part of an extended complex,
originally termed the BRAF–HDAC complex (BHC).7 As a
control, the BirA* protein was tagged with a nucleoporin nuclear
localisation signal (NLS, BirA*-NLS), to identify proteins
incidentally biotinylated by BirA* alone. Due to the presence of
unstructured N-terminal regions in LSD1, PHF21A and CoREST1,
the BirA* tag was added to their N-termini, whereas HDAC1 was
C-terminally fused to BirA* because the N-terminus forms part of
the histone deacetylase domain.18 In addition, all the constructs
contained a FLAG-tag to examine their relative expression levels in
cells. Transient transfection of HEK293T cells followed by western
blotting revealed that each of the constructs was expressed
(Fig. 1C) and that BirA*-LSD1 and HDAC1-BirA* levels approxi-
mated those of the endogenous protein (Fig. S1A, ESI†). Addition
of biotin to the media of these transfected cells caused efficient
biotinylation of a range of proteins of various molecular weights,
as visualized using a streptavidin-IR dye conjugate (Fig. 1C and
Fig. S1B, ESI†). The overall intensity of biotin labelling appeared
to be consistent across technical and biological replicates, and
between individual CoREST complex members. However, it was
noticeable that the BirA*-NLS control consistently produced
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higher levels of biotinylation in comparison to CoREST compo-
nents. This may be due to higher protein expression levels, given
the smaller size of the BirA*-NLS construct, or the absence of a
nuclear function leading to greater promiscuity of associated
proteins.
To assess the local protein environment of the CoREST
complex protein each construct was transfected independently
into HEK293T cells in triplicate (BirA*-NLS, BirA*-PHF21A,
BirA*-CoREST1) or quadruplicate (BirA*-LSD1, HDAC1-BirA*).
Biotinylated proteins were isolated from cell lysates, sonicated
for 4 min to release chromatin associated proteins (Fig. S1C,
ESI†), using streptavidin coated beads, trypsin digested and
analysed by quantitative tandem mass spectrometry. Peptide
and protein identification, label free quantitation (LFQ) and
initial data analysis were performed to identify proteins biotiny-
lated in multiple replicates of BioID with a single BirA*-fused
protein. After this initial processing, a total of 3103 proteins
were identified. Following quality control, normalisation and
imputation of missing values, students t-tests were performed
for each CoREST complex member to determine the proteins
significantly enriched compared to the BirA*-NLS control sets.
The volcano plots (Fig. 2A) show data for individually identified
proteins for each of the CoREST complex members used in the
assay. BirA*-LSD1 specifically labelled each of its potential
dimeric partners CoREST1, 2 and 3. Members of the extended
CoREST complex identified in previous studies, PHF21A,
HMG20B (BRAF35), RREB1 and GSE1 were also among the most
significantly enriched proteins. This indicates that proteins
which form part of the constitutive CoREST complex are more
likely to be identified using BioID. Interestingly, HDAC1, which
forms part of the core ternary CoREST complex, was only weakly
associated with LSD1, suggesting that the position of BirA*
(N- vs. C-terminus) and the degree of freedom from the bait
protein are important determinants for labelling. HDAC1 is
known to be present in a number of different histone modifying
complexes, including Sin3, NuRD and MiDAC.4,5 Consistent with
this, we were able to identify numerous components of these
complexes, Sin3A/B, MTA1/2/3 and ELMSAN1. To examine
whether components of the CoREST complex overlap with
members of other HDAC1/2 containing complexes, we plotted
the CoREST-proximal proteins against the known components of
the other class-I HDAC containing complexes (Fig. 2C). We find
that there is relatively little overlap in terms of shared components
between CoREST and other complexes, with only HDAC1 consis-
tently associating with multiple complexes as would be expected.
This is significant, because it suggests that LSD1/CoREST operates
in a chromatin environment that is independent of other HDAC1
containing complexes (Sin3A, NuRD and MiDAC).
BioID identifies the majority of known CoREST associated
proteins and significantly extends the list of potential
cooperating factors
One of the strengths of our study is that we were able to test
multiple components of the same complex individually and
therefore have increased confidence in the targets identified.
To generate a definitive picture of the proximal protein
Fig. 1 CoREST complex members tagged with BirA* expressed in HEK293T cells biotinylated proximal proteins. (A) Schematic diagram showing the
ternary CoREST complex (LSD1/CoREST1/HDAC1), their preferred substrates in histone H3 and mode of assembly. (B) Schematic diagram of the BirA*-
tagged proteins used in the study. The relative position of BirA* and FLAG-tags are indicated. (C) Anti-FLAG and anti-Tubulin antibodies were used (on the
same blot) to test the relative expression of BirA*-tagged proteins (upper panel) in HEK293T cells. Proteins biotinylated by the indicated constructs were
detected by probing western blot membranes with streptavidin-IR800. Each lane represents an individual biological replicate used in the BioID study.


























































































Mol. Omics This journal is © The Royal Society of Chemistry 2021
environment surrounding the CoREST complex we applied a
stringent cutoff to our dataset that only proteins that were
significantly enriched with 3 out of 4 bait proteins would
qualify as CoREST-associated (Fig. 2B and Table T1, ESI†).
While strict, this still allows some leeway for the position of
BirA* within the complex and its accessibility for labelling
nearby proteins. Application of these criteria gives us a list of
302 out of 854 proteins (35% of total), which includes almost all
known CoREST complex components (Fig. 2C, 16/18 proteins),
with the exception of CTBP1 and 2, which are only labelled by
BirA*-PHF21A. This is a high degree of overlap considering
that HDAC1 has 100 unique targets in separate class-I HDAC
complexes (Fig. 2C). We hypothesize that this list of 302
proteins contains a number of factors which cooperate
functionally with the CoREST complex, including histone
modifying enzymes, histone binding proteins and transcription
factors. We would also expect there to be substrates of both
LSD1 and HDAC1 among this group since the signal from
transient protein–protein interactions would accumulate over
the 18 hour biotinylation period. As shown in Fig. 3, we
observed a significant association of both chromatin modifying
and chromatin associated factors. This included the H3K4
methyltransferases, KMT2B (MLL2) and KMT2D (MLL4), which
methylate distinct regions of the genome as part of discrete
multi-subunit complexes.25 The proximity of these methyltrans-
ferases suggests a degree of overlap in the methylation/
demethylation of H3K4, as observed during transcriptional
cycling.26 We also observed an association of the CoREST
complex with two non-canonical polycomb repressive
complexes, PRC1.1 and PRC1.6. KDM2B is a lysine demethylase
which can be targeted to unmethylated CpG islands through its
CXXC domain, and along with BCOR, helps PRC1.1 maintain
the integrity of polycomb domains throughout the genome.27
KDM2B demethylates H3K4me3,28 while LSD1 can only
demethylate H3K4me/me2, which highlights the possibility
for synergy between CoREST and PRC1.1 complexes in
removing this modification of transcriptionally active chromatin.
We also identified E2F6, L3MTBL2 and MGA, three components
of PRC1.6, which is required for the repression of meiotic and
germ-line-specific genes.29 In addition to histone writers, there
were a number of methyl-lysine readers, including the chromo-
domain containing proteins, CHD3, 4, 6, 7 and 8, which fit the
role of LSD1 as a regulator of histone methylation. There were also
26 different transcription factors, including previously known
CoREST components (ZNF516, ZNF217, ZMYM2 and ZMYM3)
and novel associations, such as SATB1 (and its homolog, SATB2),
Fig. 2 Identification of CoREST complex proximal proteins. (A) Volcano plots of LFQ data from BirA-tagged bait proteins versus the BirA-NLS control
are shown. Two levels of stringency for the Student’s t-test were utilised based on the S0 parameter in Perseus which controls the relative importance of
a t-test p value and difference between the means; S0 = 1, a lower stringency level (orange squares), and S0 = 2 a higher stringency level (solid black
lines). All subsequent analysis was performed on proteins significantly enriched in the higher stringency analysis. Previously known interacting proteins (as
determined from BioGRID67) are highlighted (blue squares) and components of the CoREST complex labelled for reference. (B) Significantly enriched
proteins for each BirA*-fused CoREST complex member were determined by students t-tests at high stringency (S0 = 2). The proximal proteins for each
CoREST complex component were compared and shown to overlap substantially. (C) A heat-map was plotted based on the students t-test differences
(vs. BirA*-NLS) for association of class-I HDAC complexes components with the indicated CoREST components.
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which, when phosphorylated, associates with HDAC1 and causes
transcriptional repression.30 Unexpectedly, we also identified
a significant number of cell cycle related factors, in particular,
components and regulators of the anaphase promoting complex/
cyclosome (APC/C): ANAPC1, CDC23, BUB1 and BUB1B.31
Collectively, these data indicate the CoREST complex occupies a
discrete space within the nucleus with a specific subset of
transcription factors and chromatin modifiers, and importantly,
these appear to be largely independent of other class-I HDAC
complexes.
Identification of CoREST associated proteins during ES cell
differentiation
Many of the major proteomic studies of the CoREST complex
have used either HEK293T9 or HeLa cell lines.7,8,17 While useful
biochemical tools, these are transformed cells that do not
faithfully model the physiological and developmental roles of
CoREST in vivo. Lsd1 is an essential gene in mice, with
embryonic lethality occurring prior to gastrulation at e6.5
days.32–34 Embryonic stem (ES) cells are a model for cells of
the inner cell mass (e3.5 days) and are able to proliferate
normally in the absence of LSD1. However, Lsd1 null ES cells
are unable to differentiate properly, showing mis-regulation of
major differentiation pathways and elevated levels of cells
death.32,33 We took advantage of Lsd1 conditional knockout
(cKO) ES cells to stably reintroduce our BirA*-LSD1 construct,
such that it was the only LSD1 protein being expressed (Fig. 4A).
In parallel, we also generated BirA*-NLS control cells using the
same parental ES cell line. Western blotting for LSD1 showed that
BirA*-LSD1 is expressed at a lower level than the endogenous
LSD1 protein. However, upon differentiation to embryoid bodies,
we found that BirA*-LSD1 was able to rescue the growth and
differentiation defects observed in Lsd1-KO cells (Fig. 4B, C and
ref. 32), confirming that the fusion protein is functional
and capable of replacing endogenous LSD1. We have thus
generated a flexible primary cell system in which to examine the
proximal protein environment of LSD1.
In addition to the role of the LSD1 in pluripotent ES cells, we
wanted to explore the changing proteomic environment of
the CoREST complex in actively differentiating cells. We
hypothesised that LSD1 would likely exchange its coterie of
associated proteins as cells transitioned from one lineage to
another. To test this, we treated BirA*-NLS and BirA*-LSD1 ES
cells with retinoic acid (RA) to stimulate ES cell differentiation
and generated biotin labelled extracts at 0, 24 and 66 hours
time points (Fig. 5A). To confirm that the cells were undergoing
differentiation we performed western blotting for stem cell
(OCT4 and NANOG) and lineage specific (GATA4) markers
Fig. 3 CoREST associated proteins and their biological functions. Proteins significantly associated with three or more components of the CoREST
complex (S0 = 2) using BioID, were categorized by their individual functions using ClueGO68 and mapped in Cytoscape.54
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(Fig. S2, ESI†). As expected, both OCT4 and NANOG levels
decreased over time and were absent by the 66 hours time
point, while GATA4 expression was increased. Samples were
then processed for BioID in an identical manner to the previous
experiments in HEK293T cells, with LSD1-proximal proteins
identified by mass-spectrometry and those showing significant
quantitative enrichment over BirA*-NLS plotted for each time
point (Fig. 5B). In total we identified 156 individual LSD1-
associated proteins across the time course (Fig. 5C and Table
T2, ESI†). Immediately apparent is that all of the core CoREST
complex members (18 out of 18) are among the 67 proteins
which remain stably associated during differentiation (Fig. 5C),
with CoREST1/2/3, HDAC1/2, PHF21A, GSE1 and ZMYM2/3
among the most significantly enriched proteins identified
in all samples. However, we also identified proteins whose
association is specific to pluripotent cells (RA 0 h, 14 proteins),
early differentiation (RA 24 h, 16 proteins) and differentiated
cells (RA 66 h, 35 proteins). Indeed, principal component
analysis (PCA) of LSD1 proximal proteins at the three different
time points (using four independent BirA*-LSD1 clones)
reflected a transition in CoREST environment during the
process of differentiation (Fig. 5D). To some extent, this may
reflect the changes in gene expression during differentiation,
typified by the association with the co-repressor, NRIP1 (24/66
hours), whose expression is induced by RA treatment. However,
the expression of most differentiation-specific targets (CBX3,
EHMT2, JARID1C, TFDP1, etc.) are unaffected by differentiation
and therefore represents a distinct set of associated proteins
during the ES to somatic cell transition. Intriguingly, among
this group is the stem cell master regulator, OCT4 (RA 24 h
only). OCT4 has a pro-differentiation role in early
embryogenesis35,36 and has previously been demonstrated to
bind LSD1 containing complexes,37–39 which our data suggest
may be induced by differentiation.
The LSD1/CoREST interactome in ES cells is enriched from
chromatin modifying complexes
The advantage of the BioID approach is that unlike co-
purification methods, it does not require direct binding. We
detected a number of protein complexes with chromatin
modifying activities that presumably are proximal to the
CoREST complex and whose activity is complimentary to its
demethylase/deacetylase activity. Two core components of the
MuvB complex (LIN9 and LIN54), as well as the associated
protein MYBL2, were identified at all 3 time points (Fig. 6A).
The MuvB complex plays dual roles in regulating the cell cycle.
During G0 and early G1 MuvB forms part of the DREAM
complex which represses G1/S and G2/M phase genes.40,41
While during late G1 MuvB dissociates from the DREAM
complex and associates with MYBL2, forming the Myb-MuvB
(MMB) complex,42 which stimulates the expression of genes
that are important for G2/M phases.43 We also detected
Fig. 4 BirA*-LSD1 expression rescues the loss of function phenotype in Lsd1-knockout (Lsd1/) ES cells. A, western blot showing endogenous LSD1, or
BirA*-LSD1 in Lsd1/ and Lsd1Lox/ ES cells, using anti-FLAG, or anti-LSD1 antibodies as indicated. B, Representative images of embryoid bodies (EBs) at
day 5 and day 7 of differentiation from the ES cell lines as indicated. C, Average EB diameter over a 7-day time course. All values are shown as mean  SD.
All data points were assessed for statistical significance relative to control cells (Lsd1Lox/) using a student’s t-test (p r 0.05 = *, p r 0.01 = **, p r
0.001 = ***). All significant values are shown.
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potentially cooperating methyltransferases and demethylases.
KDM5A (0/24/66 hours) and KDM5B (66 hours) both remove
H3K4me3.44,45 KDM5B regulates H3K4 methylation during ES
cell differentiation and acts in concert with LSD1 to regulate
H3K4 methylation at highly active ES cell genes.46 This lends
credence to the idea of cooperation between pairs of demethy-
lases leading to complete H3K4 demethylation in ES cells, as is
the case for LSD1 and KDM5B in breast cancer cells.47
Consistent with CoRESTs role as a transcriptional repressor,
we also identified an H3K9me3 methyltransferase, SETDB1,
and its binding partner ATF7IP (both proteins identified at
all time points). ATF7IP is proposed to stimulate SETDB1
activity by promoting its nuclear import and preventing its
degradation.48,49 Among the differentiation-specific proximal
proteins were CBX3, EHMT2 (G9a) and TFDP1, components of
the non-canonical PRC1 complex, PRC1.6/E2F6.com.29 E2F6
was not present in our ES cells experiments but was identified
by all of the bait proteins used in HEK293T cells (Fig. 3).
EHMT2 is a KMT for H3K9me2, suggesting that the application
of this heterochromatic mark may be coordinated with the
removal of H3K4me/me2 by LSD1. EHMT2 has also been shown
to methylate the N-terminus of LSD1 at K114, a mark which is
recognized by the chromodomain of CHD1,50 indicating that
in addition to identifying LSD1 substrates, BioID can
identify enzymes which also modify LSD1. Unexpectedly, the
5-methylcytosine hydroxylases, TET1 and TET2, were identified
as differentiation specific CoREST-proximal proteins (Fig. 6).
LSD1 activity has been linked to DNA methylation through the
stabilization of DNMT1.33 Although a potential substrate of
LSD1, DNMT1 was not present in our BioID data from either ES
or HEK293T cells. The identification of both TET1 and TET2
(TET3 is not expressed in ES or somatic cells) and 5-methyl-CpG
binding factor, ZBTB33 (aka KAISO) all lend credence to the
association of H3K4me/me2 demethylation and DNA methylation
Fig. 5 ES cells were differentiated with retinoic acid (RA) to identify the temporal LSD1 interactome during differentiation. (A) Schematic diagram
showing the time course for RA treatment and biotin labelling used for BioID experiments. (B) Volcano plots for the indicated time points of RA treatment.
Two levels of stringency for the Student’s t-test were utilised based on the S0 parameter in Perseus which controls the relative importance of a t-test
p value and difference between the means; S0 = 1, a lower stringency level (orange squares), and S0 = 2 a higher stringency level (solid black lines).
All subsequent analysis was performed on proteins significantly enriched in the higher stringency analysis. Previously known interacting proteins
(as determined from BioGRID67) are highlighted (blue squares) and components of the CoREST complex labelled for reference. (C) Venn diagram
showing proteins significantly associated with BirA*-LSD1 (S0 = 2) at the indicated time-points following RA treatment. (D) Principal component analysis
(PCA) was performed on individual BirA*-LSD1 BioID experiments (n = 4) at the indicated time-points.
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activities (Fig. 6B) that will require further investigation. As in
HEK293T cells (Fig. 2C), we again failed to identify components of
other HDAC1-containing complexes (Sin3A, NuRD and MiDAC) in
ES cells using BirA*-LSD1, which supports the notion that LSD1
operates in chromatin environment which is exclusive to CoREST.
We found a consistent association with the ATPase/chromatin
remodelling protein, CHD4. CHD4 forms part of the nucleosome
and remodelling and deacetylase (NuRD) complex51 that has been
proposed to also contain LSD1.52 However, we find no association
of LSD1 with NuRD subunits (MTA1-3, MBD3, GATAD2A) in ES
cells (Fig. 6). More recently, CHD4 was found to form a complex
with ADNP (activity dependent neuroprotective protein) and
heterochromatin protein 1 gamma (HP1g, aka CBX3), called
ChAHP, which negatively regulates chromatin accessibility.53
Intriguingly, we detect ADNP, CHD4 and CBX3 with BirA*-LSD1
in ES cells; and observe a significant overlap between unique
CHD4 interactors53 and LSD1-associated proteins (ZNF592,
ZMYND8, ZFP462, POGZ, EHMT2, CHAMP1, ZFP280), suggesting
that CoREST and ChAHP complexes may cooperate to regulate
chromatin accessibility.
Finally, we used Cytoscape54 to plot a network of LSD1
interacting proteins based on known associations in combi-
nation with intensity-based absolute quantification (iBAQ)
values for individual proteins (Fig. 7A). iBAQ values derived from
BioID give an indication of both the abundance of proteins
within a sample and their proximity to the N-terminus of LSD1
for labelling. This network identifies the presence of potential
cooperating complexes, such as MMB and ChAHP (discussed
above), and intriguingly, 6 of 6 components of the RNA pol III
general transcription factor 3C (GTF3C). GTF3C binds to the
Fig. 6 LSD1–CoREST has a dynamic complexome during ES cell differentiation. (A) Venn diagram showing number and names of proteins significantly
associated with BirA*-LSD1 (students t-test, S0 = 2) at the indicated time-points following RA treatment. (B) Table showing LSD1 associated chromatin
complexes, subunits identified with BirA*-LSD1, their extended complex components and biological activities.
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internal promoters of the majority of RNA pol III genes (including
tRNAs) and helps recruit GTF3B for transcription initiation.55 The
presence of all six GTF3C subunits is compelling and suggests an
unrecognised role for the CoREST complex in regulating tRNA
transcription. The iBAQ values derived from LSD1-associated
proteins also give an indication of their stoichiometry within
the complex and proximity to CoREST. Unsurprisingly, 14 of
20 proteins with the highest iBAQ values are components of the
CoREST complex itself (Fig. 7B). All 3 members of the ChAHP
complex (CHD4, ADNP and CBX3) are among this group,
reiterating the potential association of this complex with CoREST.
iBAQ values across the time-course of RA treatment also allows us
to identify changes in stoichiometry of LSD1-associated proteins.
We detect a 4-fold increase in ZNF516 association for instance,
which correlates with increased levels of Znf516 transcription
during ES cell differentiation. LSD1 has three potential hetero-
dimeric partners, CoREST1-3. CoREST2 is the major partner in
pluripotent ES cells (Fig. 7B), but decreases during differentiation
Fig. 7 LSD1-interactome network and iBAQ values reveal shifting stoichiometry of the CoREST complex. (A) Cytoscape was used to generate a network
of LSD1-interacting proteins in ES cells. The intensity-based absolute quantification (iBAQ) values for individually isolated proteins is indicated by the size
of the node (green circles). LSD1-associated complexes of interest, including: MMB, ChAHP and GTF3C are indicated by coloured rectangles. (B) The top
20 proteins with the highest iBAQ values are shown for each time-point of retinoic acid (RA) treatment. The three main components of the ChAHP
complex are coloured in orange. All values are shown as mean  SD (C) iBAQ values for the three CoREST homologues is shown over the time course of
RA mediated differentiation.
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to levels equivalent to CoREST1. CoREST3 is by far the junior
partner among the three proteins, although it shows increased
binding to LSD1 following RA treatment (Fig. 7C). Collectively, our
data shows subtle changes within the CoREST complex during
differentiation, and a chromatin environment composed of con-
stitutively associated complexes (MMB, GTF3C, SETDB1/ATF7IP)
and a changing set of partners (e.g. TET1/TET2) reflecting the
alteration in cellular context.
Discussion
Understanding the extended ‘social network’ of a protein
(binding partners, substrates, modifying enzymes, complex
subunits, etc.) is crucial to understanding its molecular
mechanism in cells. Historically, proteomic approaches have
taken advantage of yeast two-hybrid, or affinity-purification
coupled to mass-spectrometry, to identify candidate lists of
associated proteins. The latter relies on protein partners
remaining bound throughout cell lysis and then subsequent
wash-steps to allow for their identification. While this technique
has been hugely powerful56,57 it potentially misses many weak or
transient associations that occur throughout a dynamic
proteome. Here we have explored the interactome of the protein
demethylase, LSD1, using BioID. BioID covalently attaches biotin
to protein partners within a range of B10 nm allowing transient
associations to be captured.22,23,58 To increase the confidence of
protein partners identified, we performed BioID for all of the
core components of the CoREST complex: LSD1, CoREST1,
HDAC1 and PHF21A. In each case, the most enriched proteins
were components of the CoREST complex (Fig. 2A and C),
validating the assay and also indicating that stable complex
components are the proteins most likely to be identified.
To produce a definitive set of CoREST associated factors in
HEK293T cells we applied a stringent cut-off, that potential
partners must be enriched with 3 out 4 bait proteins, which
narrowed the list to 302 candidate proteins, including numerous
transcription factors and chromatin associated factors (Fig. 2
and 3). Among this group were 16 of 18 core CoREST complexes
members (CTBP1 was only found with BirA-PHF21A), that gives
us confidence in the extended list of previously unidentified
partners. For instance, we find a strong overlap with the CoREST
complex and histone methylation, including readers (CHD3, 4, 6,
7 and 8), writers (KMT2B and KMT2D) and erasers (KDM2B),
suggesting functional cooperativity in the regulation of H3K4
and H3K9 methylation. PRC2 complex components (which
regulates H3K27 methylation) were absent from our survey,
but we did find PRC1.1 (KDM2B, BCOR) and PRC1.6 (E2F6,
L3MTBL2, MGA), which indicates functional overlap between
complexes that repress transcription.
Given these data, it is worth considering the practical
labelling distance of BirA* which has been previously
determined at B10 nm (B100 Å).58 While this distance is
biologically relevant for studying the CoREST complex, LSD1
has an elongated structure B150 Å in length15 and a nucleo-
some octamer is B65 Å in length,59 suggesting that the physical
arrangement of proteins in a complex might be a factor for
biotin-labelling. If so, then BioID may identify only a subset of
components within a given multi-subunit complex, while
preferentially labelling others (e.g. ZMYM2, Fig. 7). Our data
from LSD1-associated complexes suggests this might be the
case. BirA*-LSD1 identified three components of the MMB
complex in ES cells, MYBL2/LIN9/LIN54, but not extended
complex members such as RBBP4/LIN37/LIN52 (Fig. 6A and B),
suggesting that only the former proteins are located physically in
proximity to LSD1. One of the strengths of BioID is that it has the
capacity to identify weak and transient associations, including,
enzyme substrates. We did not detect either p53 or DNMT1, both
known substrates of LSD1,33,60 in our experiments, although
both proteins are expressed in HEK293T and ES cells. However,
we did detect an association between LSD1 and KIF11, a kinesin-
like protein whose ATPase activity is regulated by Lys-acetylation
and is a substrate for HDAC1.61
Conclusions
In total, we have performed 16 independent BioID experiments
for LSD1 in three different cell types (ES, ES + RA and
HEK293T). Interestingly, only 43 out of 577 proximal proteins
(7% of total) were identified under all conditions (Table T3,
ESI†), which underlines the importance of cell type when
performing or comparing proteomics studies. Of these 43
proteins, 15 have been directly linked to LSD1 function and/
or the CoREST complex, including all three CoREST family
members, HDAC2, PHF21A, ZMYM2/3, GSE1 and CTBP1. In
addition, more recently identified partners such as, SFMBT1,
which forms a complex with LSD1–CoREST to repress gene
targets, including cell cycle dependent repression of histone
genes, were also identified using BioID.62,63 Among the
extended group are LIN9 and MYBL2, part of the MMB complex
described in ES cells above, inferring a functional link between
MMB and LSD1 in multiple cell types.
Our data, and that from many other studies64 suggest BioID is
an excellent method for examining protein–protein associations
in cells enabling sampling of the proteome in a temporal
fashion. Biotin ligation methods should prove to be a powerful
tool for examining the complex association of proteins in cells,
in particular for the large multi-protein complexes that regulate
chromatin structure and gene expression. Our application of
BioID in this study has identified a definitive network of LSD1
and CoREST complex associated proteins in three different cell
types that should be a valuable resource for the field as we seek
to address their fundamental roles during development and
assess their potential as therapeutic targets.
Materials and methods
Cell culture
All ES cell experiments used stably transfected Lsd1lox/D3 cells32
cultured as described in M15 + leukemia inhibitory factor (LIF)
media as described previously:65 500 mL Knockout Dulbecco’s
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Modified Eagle Medium (DMEM) (GIBCO; 10829-018), 90 mL
Foetal Bovine Serum (FBS, Seralab; EU 000F), 6 mL Penicillin/
Streptomycin/Glutamine-100 (GIBCO; 10378-016), 600 mL
50 mM b-mercaptoethanol (Fisher Scientific; 125472500),
25 mL LIF (prepared in house). To induce Lsd1 deletion cells
were cultured with 4-hydroxytamoxifen (OHT) as described
previously.3 HEK293T cells were cultured in M10 media:
500 mL DMEM (GIBCO; 41963-039), 54 mL FBS, 6 mL
Penicillin/Streptomycin/Glutamine-100 (GIBCO; 10378-016).
To form embryoid bodies (EBs), ES cells were resuspended in
differentiation media: 500 mL DMEM/F-12 (1 : 1) (GIBCO;
11320-003), 56.2 mL FBS (Seralab; EU 000F), 6 mL Penicillin/
Streptomycin/Glutamine-100 (GIBCO; 10378-016), 600 mL
b-mercaptoethanol (1000) at 5  103 cells per mL. 500 cells
(100 mL) were plated in each well of low attachment-round
bottomed 96 well plates (Corning;7007). EBs were imaged each
day using a standard phase-contrast microscope with the size of
individual EBs calculated using Nikon Imaging Software. For
retinoic acid (RA) differentiation ES cells were plated down on
pre-gelatinised 15 cm culture plates in M15 + LIF media. After
24 hours M15 + LIF media was replaced with the differentiation
media described above supplemented with 1 mM RA. Cells were
harvested after 0, 24 and 66 hours.
Lipofectamine 2000 transfections
The cloning of all constructs used in the study was performed
by the PROTEX service at the University of Leicester.
For transient transfection of HEK293T cells on 10 cm plates
10 mg of plasmid DNA was incubated with 500 mL of Opti-MEM
(GIBCO; 31985062), whilst 10 mL of Lipofectamine 2000
(Thermo Fisher; 11668019) was incubated with 500 mL of
Opti-MEM separately for 5 min at room temperature. The
DNA and Lipofectamine were mixed and incubated for
20 min before being added drop-wise to cells. For experiments
in ES cells stable rescues were created. 5  105 Lsd1lox/D3 cells
were dually transfected with piggyBac insertion and transposase
vectors. 2.5 mg of each vector was incubated in the same 100 mL
of Opti-MEM while 6 mL of Lipofectamine was incubated with a
separate 100 mL of Opti-MEM at room temperature for 5 min.
The DNA and lipofectamine were then mixed and incubated for
a further 20 min before being added drop-wise to cells. 24 hours
after transfection 5  103 cells were plated on to 10 cm culture
plates. Cells were treated with 200 mg mL1 G418 (GIBCO;
10131027) for 10 days, single colonies were then picked on to
96 well round bottomed culture plates containing 50 mL of
TrypLE (GIBCO; 12604021). The TrypLE suspension was then
transferred on to a pre-gelatinised 96 well flat-bottomed plate
containing 150 mL of M15 + LIF media. Cells were expanded
before use in subsequent experiments.
Immunoblotting
Cells grown to B80% confluence were harvested for protein
extraction through washing in PBS and scraping in 1 mL PBS
prior to centrifugation at 1100 rpm for 3 minutes to pellet cells.
Cell pellets were resuspended in approximately 2–3 packed
cell volume (PCV) of protein lysis buffer. Lysates were incubated
on ice for 20 minutes and centrifuged at 14 000 rpm, 4 1C for
15 minutes to pellet cellular debris. Supernatants, containing the
whole cell protein extract, were transferred to new eppendorfs
and protein concentrations were determined with a Bradford
assay. For extraction of histones, whole cell protein extractions
were performed as described above. Following centrifugation
and removal of supernatant, pellets were resuspended in 0.4 N
H2SO4 (equal volume to volume of protein lysis buffer used).
Samples were rotated at 4 1C for 24 hours prior to centrifugation
at 14 000 rpm, 4 1C for 15 minutes to pellet cellular debris.
Supernatants containing histone proteins were transferred to
new eppendorfs and stored at80 1C. The primary and secondary
antibodies used are shown in Table T4 (ESI†). For blots used to
probe biotinylation, a streptavidin infrared dye was used.
BioID and mass spectrometry analysis
BirA* constructs were generated and transfected in to cells as
described above. Where transient transfections were used, two
10 cm plates of HEK293T cells were transfected and 24 hours later
50 mM biotin was added to the culture media for 18 hours prior to
harvesting. Stably transfected Lsd1lox/D3 ES cells expressing either
BirA*-LSD1 or BirA*-NLS (generated as described above) were
plated on to 15cm culture plates 24 hours prior to being treated
with 50 mM biotin for 18 hours before harvesting. Cells were
harvested by scraping in to 2 mL of PBS before pelleting through
centrifugation at 1100 rpm for 3 min. Pellets were lysed in 1.5 mL
of BioID lysis buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.5%
NP-40, 0.5% Triton-X100, 0.1% SDS), and rotated at 4 1C for
20 min. Samples were then sonicated for 4 min (30 seconds on/30
seconds off), using the Bioruptor Pico Sonication device. Samples
were cleared by centrifugation at 14 000 rpm at 4 1C for 15 min.
Extracts were then added to 60 mL of Streptavidin agarose beads
(Novagen; 69203-3) that had been washed 3 times in BioID lysis
buffer. Extracts were incubated with the beads overnight whilst
rotating at 4 1C. Beads were washed for 10 min in Wash Buffer
1 (2% SDS in ddH2O), Wash Buffer 2 (deoxycholate 0.2%, Triton
X-100 1%, NaCl 500 mM, EDTA 1 mM, HEPES pH 7.5 50 mM),
Wash Buffer 3 (Tris pH 8 10 mM, LiCl 250 mM, NP-40 0.5%,
deoxycholate 0.5%, Triton X-100 1%, NaCl 500 mM, EDTA 1 mM),
then twice in Wash Buffer 4 (Tris pH 7.4 50 mM, NaCl 50 mM).
Streptavidin bead IPs were washed twice in 50 mM ammonium
bicarbonate, then resuspended in 200 mL of ammonium bicarbo-
nate, reduced with 10 mM tri(2-carboxyethyl) phosphine hydro-
chloride (TCEP) and alkylated with 20 mM Iodoacetamide in the
dark at 37 1C, for 30 min. 1 mg of trypsin (Pierce, MS grade) was
added to each sample and incubated whilst shaking overnight
at 25 1C. Following trypsin digestion, streptavidin beads
were pelleted and supernatants were acidified by addition of
trifluroacetic acid to 0.4% and desalted using C18 spin columns
(ThermoFisher) according to manufacturer’s protocol. Samples
were re-suspended in 40 mL of 0.5% formic acid and 18 mL was
analysed by nanoflow LC-MS/MS using an Orbitrap Elite (Thermo
Fisher) hybrid mass spectrometer equipped with a nanospray
source, coupled to an Ultimate RSLCnano LC System (Dionex).
The system was controlled by Xcalibur 3.0.63 (Thermo Fisher) and
DCMSLink (Dionex). Peptides were desalted on-line using an
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Acclaim PepMap 100 C18 nano/capillary BioLC, 100A nanoViper
20 mm 75 mm I.D. particle size 3 mm (Fisher Scientific) at a flow
rate of 5 mL min1 and then separated using a 125 min gradient
from 5 to 35% buffer B (0.5% formic acid in 80% acetonitrile) on
an EASY-Spray column, 50 cm  50 mm ID, PepMap C18, 2 mm
particles, 100 Å pore size (Fisher Scientific) at a flow rate of
0.25 mL min1. The Orbitrap Elite was operated with a cycle of
one MS (in the Orbitrap) acquired at a resolution of 60 000 at m/z
400, with the top 20 most abundant multiply charged (2+ and
higher) ions in a given chromatographic window subjected to MS/
MS fragmentation in the linear ion trap. An FTMS target value of
1  106 and an ion trap MSn target value of 1  104 were used
with the lock mass (445.120025) enabled. Maximum FTMS scan
accumulation time of 500 ms and maximum ion trap MSn scan
accumulation time of 100 ms were used. Dynamic exclusion
was enabled with a repeat duration of 45 s with an exclusion list
of 500 and an exclusion duration of 30 s.
Mass spectrometry data analysis
All raw mass spectrometry data were analysed with MaxQuant
version 1.5.6 44. Data were searched against a human UniProt
sequence database (June 2015) using the following search
parameters: digestion set to Trypsin/P with a maximum of
2 missed cleavages, methionine oxidation and N-terminal
protein acetylation as variable modifications, cysteine carbami-
domethylation as a fixed modification, match between runs
enabled with a match time window of 0.7 min and a 20 min
alignment time window, label-free quantification enabled with
a minimum ratio count of 2, minimum number of neighbours
of 3 and an average number of neighbours of 6. A first search
precursor tolerance of 20 ppm and a main search precursor
tolerance of 4.5 ppm was used for FTMS scans and a 0.5 Da
tolerance for ITMS scans. A protein FDR of 0.01 and a peptide
FDR of 0.01 were used for identification level cut-offs. Protein
group files generated by MaxQuant were loaded into Perseus
version 1.5.5.3.66 The matrix was filtered to remove all proteins
that were potential contaminants, only identified by site and
reverse sequences. The LFQ intensities were then transformed
by log2(x), and individual LFQ columns were grouped
by experiment. Proteins were filtered to keep only those
that had a minimum of 3 valid LFQ values in at least one
group. The distribution of LFQ intensities of identified proteins
was checked to ensure standard distribution for each individual
replicate. Missing values were randomly imputed with a width of
0.3 and downshift of 1.8 from the standard deviation. In order to
identify quantitatively enriched proteins between groups two-
sided Student’s t-tests were performed with a permutation-based
FDR calculation (FDR = 0.05). Two levels of stringency for the
Student’s t-test were utilised based on the S0 parameter in
Perseus which controls the relative importance of a t-test p value
and difference between the means; S0 = 1, a lower stringency
level, and S0 = 2 a higher stringency level. All subsequent
analysis was performed on proteins significantly enriched in
the higher stringency analysis. Gene ontology and interaction
network visualisation was performed using Cytoscape (version
3.6.0).54
Experimental design and statistical rationale
For the BioID experiments in HEK293T cells transient transfections
were carried out in triplicate (BirA*-NLS, BirA*-PHF21A, BirA*-
CoREST) or quadruplicate (BirA*-LSD1, HDAC1-BirA*), with 2 
10 cm plates used per replicate. For ES cell experiments, four clones
stably expressing either BirA*-LSD1 or BirA*-NLS were seeded on to
15 cm plates (1 15 cm plate per sample). The use of at least three
biological replicates allowed for statistical determination of which
proteins in our dataset were significantly more biotinylated by the
fusion protein of interest, than the BirA*-NLS control. BirA*-NLS
was used as a control in all experiments as the LSD1–CoREST
complex which is predominantly localised to the nucleus.
Therefore, BirA*-NLS allowed us to determine which proteins were
incidentally biotinylated rather than being in close proximity to the
protein of interest. Student’s t-tests were used identify significantly
enriched proteins using a permutation-based FDR calculation
(FDR = 0.05). Student’s t-tests were performed using Perseus which
utilises the S0 parameter to weight the difference between
means, all subsequent analysis was based on proteins that were
significantly enriched using S0 = 2 which is the higher stringency
level of analysis.
Data availability
The mass spectrometry data have been deposited to the
ProteomeXchange Consortium via the PRIDE (https://www.
ebi.ac.uk/pride/archive/) partner repository with the dataset
identifier PXD017344.
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